Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H2 2017
Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H2 2017
SUMMARY
Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) pipeline Target constitutes close to 9 molecules. Out of which approximately 9 molecules are developed by Companies. The latest report Tyrosine Protein Kinase ITKTSK - Pipeline Review, H2 2017, outlays comprehensive information on the Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Tyrosine-protein kinase ITK/TSK or interleukin-2-inducible T-cell kinase or simply ITK is a protein encoded by the ITK gene. It plays an essential role in regulation of the adaptive immune response. When antigen presenting cells (APC) activate T-cell receptor (TCR) a series of phosphorylation lead to the recruitment of ITK to the cell membrane, stimulate TCR receptor, where it is phosphorylated by LCK. Phosphorylation leads to ITK autophosphorylation and full activation. It regulates the development, function and differentiation of conventional T-cells and nonconventional NKT-cells. The molecules developed by companies in Filing rejected/Withdrawn, Phase II, Preclinical and Discovery stages are 1, 2, 4 and 2 respectively. Report covers products from therapy areas Immunology, Oncology, Dermatology, Gastrointestinal, Genetic Disorders and Respiratory which include indications Psoriasis, Rheumatoid Arthritis, Allergies, Angiosarcoma, Asthma, Atopic Dermatitis, Bile Duct Cancer (Cholangiocarcinoma), Chondrosarcoma, Colorectal Cancer, Ewing Sarcoma, Extrahepatic Bile Duct Cancer, Fallopian Tube Cancer, Follicular Thyroid Cancer, Gallbladder Cancer, Glioblastoma Multiforme (GBM), Gliosarcoma, Inflammation, Liposarcoma, Merkel Cell Carcinoma, Metastatic Bile Duct Cancer, Metastatic Breast Cancer, Metastatic Renal Cell Carcinoma, Neuroblastoma, Osteosarcoma, Ovarian Cancer, Papillary Thyroid Cancer, Peritoneal Cancer, Recurrent Glioblastoma Multiforme (GBM), Rhabdomyosarcoma, Soft Tissue Sarcoma, Thyroid Cancer, Ulcerative Colitis, Vitiligo and Von Hippel-Lindau Syndrome.
Furthermore, this report also reviews key players involved in Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) pipeline Target constitutes close to 9 molecules. Out of which approximately 9 molecules are developed by Companies. The latest report Tyrosine Protein Kinase ITKTSK - Pipeline Review, H2 2017, outlays comprehensive information on the Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Tyrosine-protein kinase ITK/TSK or interleukin-2-inducible T-cell kinase or simply ITK is a protein encoded by the ITK gene. It plays an essential role in regulation of the adaptive immune response. When antigen presenting cells (APC) activate T-cell receptor (TCR) a series of phosphorylation lead to the recruitment of ITK to the cell membrane, stimulate TCR receptor, where it is phosphorylated by LCK. Phosphorylation leads to ITK autophosphorylation and full activation. It regulates the development, function and differentiation of conventional T-cells and nonconventional NKT-cells. The molecules developed by companies in Filing rejected/Withdrawn, Phase II, Preclinical and Discovery stages are 1, 2, 4 and 2 respectively. Report covers products from therapy areas Immunology, Oncology, Dermatology, Gastrointestinal, Genetic Disorders and Respiratory which include indications Psoriasis, Rheumatoid Arthritis, Allergies, Angiosarcoma, Asthma, Atopic Dermatitis, Bile Duct Cancer (Cholangiocarcinoma), Chondrosarcoma, Colorectal Cancer, Ewing Sarcoma, Extrahepatic Bile Duct Cancer, Fallopian Tube Cancer, Follicular Thyroid Cancer, Gallbladder Cancer, Glioblastoma Multiforme (GBM), Gliosarcoma, Inflammation, Liposarcoma, Merkel Cell Carcinoma, Metastatic Bile Duct Cancer, Metastatic Breast Cancer, Metastatic Renal Cell Carcinoma, Neuroblastoma, Osteosarcoma, Ovarian Cancer, Papillary Thyroid Cancer, Peritoneal Cancer, Recurrent Glioblastoma Multiforme (GBM), Rhabdomyosarcoma, Soft Tissue Sarcoma, Thyroid Cancer, Ulcerative Colitis, Vitiligo and Von Hippel-Lindau Syndrome.
Furthermore, this report also reviews key players involved in Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2)
- The report reviews Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Overview
Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Companies Involved in Therapeutics Development
Aclaris Therapeutics Inc
Arrien Pharmaceuticals LLC
Corvus Pharmaceuticals Inc
Genentech Inc
Japan Tobacco Inc
Novartis AG
Principia Biopharma Inc
Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Drug Profiles
ARN-4079 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GNE-4997 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JTE-051 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pazopanib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pazopanib hydrochloride + pembrolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRN-694 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ITK and TXK for Psoriasis and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ITK for Autoimmune Disorders, Chronic Inflammation and Colorectal Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ITK for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Dormant Products
Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Discontinued Products
Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases
Jul 21, 2016: Mateon Announces Enrollment of First Patient in Phase 2 Portion of PAZOFOS Study in Recurrent Ovarian Cancer
Mar 16, 2015: Cancer drug may reduce bleeding in patients with rare genetic disorder, HHT
Sep 01, 2014: Arrien Pharmaceuticals Provides Update on ARN-4079
Apr 01, 2014: Results from phase III patient preference study of GSK’s Votrient (pazopanib) vs. Sutent (sunitinib) in advanced renal cell carcinoma published in Journal of Clinical Oncology
Mar 31, 2014: Votrient as maintenance therapy for advanced ovarian cancer in the EU
Aug 21, 2013: Pazopanib shows better quality-of-life in advanced kidney cancer
Aug 07, 2013: GSK seeks additional indication approval for Votrient from EMA
Jul 11, 2013: GlaxoSmithKline's cancer drug Votrient receives full EU approval
Jun 01, 2013: GSK's Votrient Meets Primary Endpoint In Phase III Clinical Trial As Maintenance Therapy In Women With Advanced Epithelial Ovarian Cancer
Jan 08, 2013: Combination Of Pazopanib And Paclitaxel May Slow Anaplastic Thyroid Cancer, Mayo Clinic Study Shows
Oct 01, 2012: GlaxoSmithKline's Votrient Meets Primary Endpoint In Pivotal Phase III Study Of Advanced Renal Cell Carcinoma
Aug 07, 2012: GlaxoSmithKline Receives Marketing Authorization From European Commission For Pazopanib
May 25, 2012: GSK Receives Positive Opinion From European CHMP For Pazopanib In Treatment Of Patients With Certain Advanced Soft Tissue Sarcomas
Apr 26, 2012: GSK's Votrient Receives FDA Approval For Treatment Of Advanced Soft Tissue Sarcoma
Mar 20, 2012: GSK Announces Positive Vote From FDA Panel For Pazopanib In Certain Advanced Soft Tissue Sarcomas
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Overview
Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Companies Involved in Therapeutics Development
Aclaris Therapeutics Inc
Arrien Pharmaceuticals LLC
Corvus Pharmaceuticals Inc
Genentech Inc
Japan Tobacco Inc
Novartis AG
Principia Biopharma Inc
Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Drug Profiles
ARN-4079 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GNE-4997 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JTE-051 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pazopanib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pazopanib hydrochloride + pembrolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRN-694 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ITK and TXK for Psoriasis and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ITK for Autoimmune Disorders, Chronic Inflammation and Colorectal Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ITK for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Dormant Products
Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Discontinued Products
Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases
Jul 21, 2016: Mateon Announces Enrollment of First Patient in Phase 2 Portion of PAZOFOS Study in Recurrent Ovarian Cancer
Mar 16, 2015: Cancer drug may reduce bleeding in patients with rare genetic disorder, HHT
Sep 01, 2014: Arrien Pharmaceuticals Provides Update on ARN-4079
Apr 01, 2014: Results from phase III patient preference study of GSK’s Votrient (pazopanib) vs. Sutent (sunitinib) in advanced renal cell carcinoma published in Journal of Clinical Oncology
Mar 31, 2014: Votrient as maintenance therapy for advanced ovarian cancer in the EU
Aug 21, 2013: Pazopanib shows better quality-of-life in advanced kidney cancer
Aug 07, 2013: GSK seeks additional indication approval for Votrient from EMA
Jul 11, 2013: GlaxoSmithKline's cancer drug Votrient receives full EU approval
Jun 01, 2013: GSK's Votrient Meets Primary Endpoint In Phase III Clinical Trial As Maintenance Therapy In Women With Advanced Epithelial Ovarian Cancer
Jan 08, 2013: Combination Of Pazopanib And Paclitaxel May Slow Anaplastic Thyroid Cancer, Mayo Clinic Study Shows
Oct 01, 2012: GlaxoSmithKline's Votrient Meets Primary Endpoint In Pivotal Phase III Study Of Advanced Renal Cell Carcinoma
Aug 07, 2012: GlaxoSmithKline Receives Marketing Authorization From European Commission For Pazopanib
May 25, 2012: GSK Receives Positive Opinion From European CHMP For Pazopanib In Treatment Of Patients With Certain Advanced Soft Tissue Sarcomas
Apr 26, 2012: GSK's Votrient Receives FDA Approval For Treatment Of Advanced Soft Tissue Sarcoma
Mar 20, 2012: GSK Announces Positive Vote From FDA Panel For Pazopanib In Certain Advanced Soft Tissue Sarcomas
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indications, H2 2017
Number of Products under Development by Indications, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by Aclaris Therapeutics Inc, H2 2017
Pipeline by Arrien Pharmaceuticals LLC, H2 2017
Pipeline by Corvus Pharmaceuticals Inc, H2 2017
Pipeline by Genentech Inc, H2 2017
Pipeline by Japan Tobacco Inc, H2 2017
Pipeline by Novartis AG, H2 2017
Pipeline by Principia Biopharma Inc, H2 2017
Dormant Products, H2 2017
Dormant Products, H2 2017 (Contd.1), H2 2017
Discontinued Products, H2 2017
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indications, H2 2017
Number of Products under Development by Indications, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by Aclaris Therapeutics Inc, H2 2017
Pipeline by Arrien Pharmaceuticals LLC, H2 2017
Pipeline by Corvus Pharmaceuticals Inc, H2 2017
Pipeline by Genentech Inc, H2 2017
Pipeline by Japan Tobacco Inc, H2 2017
Pipeline by Novartis AG, H2 2017
Pipeline by Principia Biopharma Inc, H2 2017
Dormant Products, H2 2017
Dormant Products, H2 2017 (Contd.1), H2 2017
Discontinued Products, H2 2017
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
COMPANIES MENTIONED
Aclaris Therapeutics Inc
Arrien Pharmaceuticals LLC
Corvus Pharmaceuticals Inc
Genentech Inc
Japan Tobacco Inc
Novartis AG
Principia Biopharma Inc
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
COMPANIES MENTIONED
Aclaris Therapeutics Inc
Arrien Pharmaceuticals LLC
Corvus Pharmaceuticals Inc
Genentech Inc
Japan Tobacco Inc
Novartis AG
Principia Biopharma Inc
